• Greenland’s recent agreements secures access to advanced rig capacity, operational support intended to facilitate future drilling activity.
• Greenland now possess the best-in-class logistics and operational infrastructure, among the largest challenges facing Arctic exploration.
• The Jameson Land Basin, where Greenland Energy is drilling, has attracted attention because it may contain significant undiscovered hydrocarbon resources.

As global energy markets continue searching for long-term supply security outside traditional producing regions, Greenland is emerging as a frontier attracting renewed attention from explorers and investors alike. Greenland (NASDAQ: GLND), a recently formed energy exploration company focused on Greenland’s hydrocarbon potential, has taken a key step toward advancing its Arctic strategy with a newly announced strategic agreements, securing advanced rig capacity and logistics for its planned onshore oil exploration program.

According to the announcement, Greenland Energy entered into a strategic agreement with Stampede Drilling, designed to support drilling operations tied to its exploration efforts in Greenland. The agreement secures access to advanced rig capacity and operational support intended to facilitate future drilling activity as the company works to evaluate and develop hydrocarbon resources in the Jameson Land Basin, an area that has drawn interest for decades because of its geological similarities to productive North Atlantic petroleum systems.

Building on the Stampede collaboration, the partnership with Halliburton forms a key component of the company’s integrated Arctic operations strategy. Together, these arrangements ensure best‑in‑class rig performance, logistics, and subsurface technology for the first onshore exploration well.

“Greenland Energy Company’s agreement with Halliburton is another pivotal milestone as we execute our 2026 drilling program and build on the momentum following our NASDAQ listing,” said Robert Price, CEO of Greenland Energy Company. “By working with Halliburton, we can tap into world‑class expertise and advanced technologies that will enhance drilling accuracy, safety, and efficiency under Arctic conditions. This agreement strengthens our operational platform and emphasizes our commitment to technical excellence and responsible development in a frontier basin.”

The agreement is significant because logistics and operational infrastructure are among the largest challenges facing Arctic exploration. Greenland’s remote geography, weather conditions and limited industrial infrastructure make drilling campaigns considerably more complex than those conducted in more established oil regions. By securing drilling support capacity early, Greenland Energy appears to be positioning itself to reduce some of those operational hurdles as it advances exploration planning.

Additional context surrounding the company’s efforts was highlighted in a BNN Bloomberg report discussing the broader operation being assembled to support Greenland oil exploration. The article described how Canadian drilling and shipping companies are being enlisted to help support Greenland Energy’s exploration initiatives in Greenland, underscoring the scale and complexity of the undertaking. The report noted that Arctic energy development requires extensive logistical coordination involving drilling contractors, transportation networks and specialized operational expertise.

The BNN Bloomberg report also emphasized growing interest in Greenland’s untapped hydrocarbon potential amid broader geopolitical and energy-security concerns. As nations and companies look to diversify supply sources, frontier regions with large undeveloped resource potential are drawing increased attention. Greenland’s location and geological profile have placed it within that conversation, particularly as technological improvements make Arctic exploration more feasible than in previous decades.

Greenland Energy itself is a relatively new player in the space. The company was formed earlier this year with a strategy centered on developing Greenland’s onshore oil resources and building a long-term position in Arctic energy exploration. The company’s focus appears to be directed primarily at the Jameson Land Basin, a region in eastern Greenland that has been studied extensively by geologists and energy companies over the years.

The basin has attracted attention because of estimates suggesting it may contain significant undiscovered hydrocarbon resources. Greenland Energy has rights connected to a substantial portion of the basin’s potential oil resources and is working to advance exploration and development initiatives in the region. While these resources remain subject to exploration risk and further evaluation, the company’s strategy is built around the belief that Greenland could become an important long-term energy jurisdiction.

The company’s approach appears to combine resource acquisition with infrastructure and operational planning. The newly announced drilling support agreement reflects that broader strategy by addressing one of the key practical requirements necessary for frontier exploration. Arctic energy projects often depend as much on logistics and execution capabilities as on geology itself, making partnerships and operational preparation especially important.

The timing of Greenland Energy’s efforts also aligns with larger trends in global energy markets. Governments and industries continue to balance the transition toward cleaner energy systems with ongoing demand for reliable oil and gas supplies. Geopolitical disruptions, shipping vulnerabilities and concerns about energy independence have all contributed to renewed interest in diversifying production sources and securing long-term resource access.

This environment has increased interest in frontier regions that were previously viewed as too remote or technically challenging. Arctic resource development remains controversial in some circles due to environmental considerations and operational risks, but supporters argue that advances in drilling technology, transportation and environmental management are improving the feasibility of responsible development.

For Greenland Energy, the challenge now will be translating strategic positioning into operational progress. Securing advanced rig capacity represents an early but meaningful step toward potential exploration activity. The company is also focused on navigating permitting requirements, logistical execution and the technical realities of Arctic drilling as it advances its plans.

However, the recent announcements suggest that Greenland Energy is committed to establishing itself as an early participant in what could become a larger push toward Arctic resource development. By combining operational partnerships with a focus on Greenland’s underexplored hydrocarbon potential, the company is seeking to build a platform around one of the world’s least developed but potentially significant frontier energy regions.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

• Mining projects have often been catalysts for both economic growth and social tension, particularly in regions where governance structures were still evolving.
• The Panguna Mine in Bougainville stands as one of the most prominent examples of this dynamic.
• Numa Numa Resources is positioning itself as part of a new chapter in Bougainville’s mining story.

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

Across the world, some of the most valuable mineral deposits sit idle not because they are depleted, but because political change—and ultimately history—left them behind. In Bougainville, Numa Numa Resources is part of a new generation of efforts seeking to revisit these sites, where past conflict is giving way to conversations about cooperation and responsible development.

Mining projects have often been catalysts for both economic growth and social tension, particularly in regions where governance structures were still evolving. In several cases globally, mines have closed due to conflict, environmental concerns or disputes over land and revenue. Over time, however, some of these projects have been reconsidered under new frameworks that prioritize community engagement and environmental stewardship. Industry guidance emphasizes that it is increasingly important to “mitigate negative impacts from their activities and maximise positive benefits for local communities and society.”

The Panguna Mine in Bougainville stands as one of the most prominent examples of this dynamic. Developed in the late 1960s and beginning production in 1972, Panguna was among the largest copper and gold mines in the world. At its peak, it generated roughly 45% of Papua New Guinea’s export revenue, underscoring its economic significance. Yet the distribution of those benefits, along with environmental impacts and disputes over land ownership, became central grievances that contributed to the Bougainville conflict, known as “The Crisis,” which lasted from 1988 to 1998.

The conflict led to the closure of the Panguna Mine and left a legacy that continues to shape discussions about resource development in the region. In 2001, the Bougainville Peace Agreement established a pathway toward autonomy and laid the groundwork for rebuilding institutions and reconsidering how natural resources might be managed in the future. Since then, Bougainville has sought to redefine the relationship between communities, government and resource developers.

Globally, second-generation mining projects have increasingly adopted new approaches that reflect lessons learned from earlier conflicts. These include more robust environmental standards, clearer benefit-sharing agreements and greater involvement of local communities in decision-making. The World Bank has noted that inclusive governance and community participation are critical to reducing conflict risks in extractive industries and improving development outcomes. This shift reflects a broader recognition that resource development is not solely a technical or economic undertaking, but a social one.

Bougainville’s experience illustrates this transition in real time. The region’s constitution places strong emphasis on customary land ownership, meaning that landowners play a central role in decisions about resource development. This has reshaped how potential mining projects are discussed, with greater focus on consultation, consent and long-term community benefits. These factors are particularly important given Bougainville’s ongoing political evolution, including its 2019 referendum in which 97.7% of voters supported independence, a result widely documented by international observers.

Within this context, Numa Numa Resources is positioning itself as part of a new chapter in Bougainville’s mining story. The company is working to develop agreements with landowners in areas associated with the Panguna deposit, which is widely considered to contain one of the largest undeveloped copper and gold resources in the region. While estimates of in-ground value can vary significantly depending on market conditions and technical factors, the scale of the resource has long been recognized by industry observers and analysts.

Numa Numa Resources is focused on building partnerships that align with Bougainville’s legal framework and customary land systems, emphasizing collaboration with landowners and local stakeholders. This approach reflects a broader shift in how mining companies engage with communities, moving away from top-down development models toward more participatory frameworks.

The concept of giving mines a “second chance” is not simply about reopening operations. It is about redefining the terms under which those operations occur. For Numa Numa Resources, this means engaging with communities early, addressing historical concerns and working within governance structures that prioritize local involvement. By doing so, the company is contributing to a broader effort to transform how resource development is perceived and managed in Bougainville.

The legacy of Panguna underscores the stakes involved. The same resource that once fueled economic growth also contributed to one of the most significant conflicts in the Pacific region. Any future development must therefore balance economic opportunity with social responsibility. This requires not only technical expertise but also trust, communication and a willingness to adapt.

As Bougainville continues to navigate its future, the idea of turning past conflict into future cooperation remains central. Projects such as those being pursued by Numa Numa Resources highlight how this transformation might unfold. By learning from history and embracing new approaches to engagement and governance, the region has an opportunity to reshape its relationship with its natural resources.

In that sense, the story of Panguna is not just about a mine. It is about how communities, governments and companies can work together to ensure that resource wealth supports stability and shared prosperity. Numa Numa Resources is one participant in that evolving process, operating at the intersection of history, opportunity and the possibility of a different path forward.

For more information, visit www.NumaNumaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to Numa Numa are available in the company’s newsroom at https://ibn.fm/NUMA

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• The company is advancing an uncommon sedimentary phosphate project in northeast Nevada aimed at supplying direct-application organic fertilizer to U.S. agriculture markets.
• NOP’s unprocessed direct-application phosphate does not have to compete with the conventional chemical agricultural input industry, and has no large scale competition in North America.
• The project’s phosphate is intended for direct field application without chemical processing, potentially reducing capital requirements compared with conventional phosphate operations.
• Phosphate has now been added to the U.S. critical minerals list, increasing strategic attention on domestic fertilizer supply chains.
• The company says drilling at its Murdock Mountain target zone has confirmed consistent phosphate mineralization across its initial six-hole campaign, with assays returning grades averaging 10.93% P2O5.
• Management believes the broader strike system could extend more than kilometres across multiple lease application areas controlled through federal permitting processes.
• Nevada Organic Phosphate plans an expanded 2026 drilling campaign while pursuing additional permits with the U.S. Bureau of Land Management.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a Canadian-based leader in organic sedimentary phosphate exploration, is positioning itself around a segment of the fertilizer market that has gained increasing attention from both agricultural producers and policymakers: domestically sourced phosphate suitable for organic and regenerative farming applications. The company is focused on the Murdock Mountain phosphate target zone in Elko County, Nevada, where it is advancing what management believes could become a large-scale source of direct-application sedimentary phosphate.

The company’s investment narrative differs from that of traditional phosphate producers. Conventional phosphate fertilizer production generally involves large-scale beneficiation and chemical processing to produce phosphoric acid and downstream fertilizers such as monoammonium phosphate (“MAP”) and diammonium phosphate (“DAP”). Nevada Organic Phosphate instead aims to supply raw phosphate rock that can be ground and applied directly to agricultural fields.

During a recent presentation at the Emerging Growth Conference, CEO Robin Dow described the project as a sedimentary phosphate system formed along the edge of an ancient inland sea that once covered parts of the western United States. According to the company, the geological setting may have contributed to relatively low contaminant levels compared with some conventional phosphate districts (https://ibn.fm/xsXSl).

Management says the company’s initial drilling campaign at Murdock Mountain produced six drill holes over approximately 1.5 kilometres of strike length. Assay work reportedly confirmed phosphate mineralization and indicated low levels of contaminants often associated with phosphate deposits, including cadmium and uranium. The company also said the upper portions of the phosphate horizon returned average grades near 11% P2O5 over roughly 4.4 metres, while one hole encountered a deeper interval grading approximately 17.5% P2O5 over 4 metres.

Rather than framing the opportunity around conventional mining economics alone, Nevada Organic Phosphate is emphasizing the potential role of direct-application phosphate in regenerative agriculture. The company argues that untreated phosphate rock can break down gradually in soil, allowing nutrient release over longer periods while avoiding some of the runoff issues associated with highly soluble phosphate fertilizers.

That positioning comes as American agriculture faces growing scrutiny over nutrient runoff into lakes and waterways. Conventional phosphate production also generates phosphogypsum waste, a byproduct that can contain radioactive elements and has become an environmental management issue in several U.S. states.

Nevada Organic Phosphate contends its planned operation would avoid many of those issues because the material would not undergo chemical upgrading. The proposed processing flow is comparatively simple: mine the rock, grind it, bag it and ship it directly to customers. The company believes this could significantly reduce capital expenditures relative to conventional phosphate projects that require beneficiation plants and acid-processing infrastructure.

Location may also work in the project’s favor. The Murdock Mountain area sits near existing transportation infrastructure, including Union Pacific rail access near the town of Montello, Nevada. Management says mined material could eventually be trucked a few kilometres to a grinding and bagging facility before rail shipment to agricultural markets across the United States.

The company’s broader exploration footprint has expanded beyond its initial lease permit area. Nevada Organic Phosphate has filed additional federal permit applications that it says could extend the potential phosphate-bearing strike length to over 26 kilometres. Across those target areas, the company estimates an exploration target mineral inventory (“ETMI”) ranging from 200 million to 220 million tonnes of phosphate-bearing material, although substantial drilling and technical work remain necessary before any formal resource classification could be established under Canadian disclosure standards.

For the initial six-kilometre target area, the company has outlined an exploration target ranging from 10 million to 46 million tonnes grading between 3% and 15%. Management attributes the wide range to the early-stage nature of exploration work and the need for further drilling to confirm continuity and thickness.

The permitting process will likely remain an important factor in the project’s timeline. Because phosphate falls under a federal leasing framework rather than standard mineral claims, the company must work through the Bureau of Land Management’s environmental and exploration approval processes. Nevada Organic Phosphate received approval for its first drill permit in late 2025 after completing environmental assessments and now plans to pursue approvals for additional permit areas.

The company believes its relatively small corporate overhead could help preserve capital during the exploration phase. Dow stated during the conference presentation that management and directors are compensated primarily through equity incentives, with direct monthly overhead estimated at roughly C$15,000 excluding exploration expenditures.

Nevada Organic Phosphate also enters the market at a time when fertilizer supply chains remain strategically important. Global phosphate markets experienced significant disruption following Russia’s invasion of Ukraine, while U.S. policymakers have increased focus on domestic critical mineral supply. Phosphate’s addition to the U.S. critical minerals list may improve visibility for domestic projects capable of supporting agricultural inputs.

Over the coming months, Nevada Organic Phosphate expects to continue drilling at Murdock Mountain while advancing permit applications across its broader Nevada land package.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF)and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, just announced that a total of 3,320,000 warrants were exercised for the purchase of 3,320,000 common shares at $0.10 a share.
• Debentures aggregating $190,000 of principal were also converted into 1,520,000 shares at a conversion price of $0.125 a share.
• 1,520,000 shares were exercised by the settlement of $152,000 of debt, with cash proceeds of $180,000 from the exercise of warrants for 1,800,000 shares applied to working capital.
• CMX’s President and CEO, Jan Alston, noted that this milestone demonstrates the confidence of the company’s management, directors, and supporting shareholders.

CMX (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, just announced that a total of 3,320,000 warrants were exercised for the purchase of 3,320,000 common shares of the company at $0.10 a share. In addition, debentures aggregating $190,000 of principal were converted into 1,520,000 shares at a conversion price of $0.125 a share (https://ibn.fm/C4Sni).

“The exercise of warrants and conversion of debentures demonstrates the confidence of management, directors, and supporting shareholders in CMX’s plan to advance the Clayton Silver project,” noted Jan Alston, President and CEO of CMX. “This kind of support over the past decade has positioned the company to capitalize on the current precious metals bull market, which in our opinion is still in its early stages,” he added (https://ibn.fm/C4Sni).

The exercised warrants were issued under a private placement completed back in 2021. Of the total issued warrants, 1,520,000 shares were exercised by the settlement of $152,000 of debt, with cash proceeds of $180,000 from the exercise of warrants for 1,800,000 shares applied to working capital.

This marks a key moment for CMX, specifically for its 100%-owned flagship asset, the Clayton Silver property located in the Bayhorse Mining District of central Idaho. It is also timely, given that, beginning in the spring of this year, the company plans to conduct the first comprehensive geophysical program over the mine and its surrounding structures, including a 3-D Direct Current Induced Polarization (“DCIP”) survey and a Magnetotelluric (“MT”) survey. The surveys will delineate known structures, identify extensions of partially mined historic ore bodies, and look for parallel vein systems, as well as potential deeper sources of mineralization. These are important steps preceding diamond drilling planned to test priority targets (https://ibn.fm/AaLhL).

Mining operations at the company’s Clayton Silver property date back to the early 1900’s when Henry Ford owned the claims for the lead production. From 1935 to 1986, operations were continuous, with recorded production over those 50 years totaling approximately 7 million ounces of silver, along with lead, zinc, copper, and minor gold from an estimated 2.15 million tons of ore (https://ibn.fm/BUtb3). Over the next several years, CMX’s management expects to put a sizable investment into its drilling programs to realize the site’s significant untapped potential.

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF)and may include paid advertising.

• The company has signed an option agreement to acquire a 100% interest in the Hopkins Rare Earths Project in northern Ontario.
• The property covers approximately 5,900 hectares within the Clay-Howells Alkalic Rock Complex, and a geological setting associated with rare earth element (“REE”) exploration, with planned exploration includes airborne geophysics, radiometric surveys, mapping, and geochemical sampling.
• Management says the acquisition strengthens Powermax’s growing North American REE portfolio alongside projects in British Columbia, Ontario, and Wyoming.
• Growing Western interest in domestic REE supply chains continues to support exploration activity across Canada and the United States.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, is continuing to expand its rare earth element exploration portfolio with the proposed acquisition of the Hopkins Rare Earths Project in northern Ontario, a move that further cements the company’s role within the growing North American critical minerals sector.

The company announced that it has entered into an option agreement to acquire a 100% interest in the Hopkins project, subject to a 2% net smelter returns royalty (https://ibn.fm/1e2yn). The Hopkins property consists of 13 multicell mining claims covering approximately 5,900 hectares in Hopkins and Mowbray townships in northern Ontario. The area is accessible through existing regional infrastructure, including the Trans-Canada Highway, provincial roads, logging routes, and nearby transportation corridors.

Management said the project aligns with the company’s broader strategy of assembling a diversified portfolio of REE-focused exploration opportunities across stable North American jurisdictions.

The geological interest surrounding the property centers on its location within the Clay-Howells Alkalic Rock Complex, a Late Precambrian intrusive system situated within the Kapuskasing Subprovince of the Superior Province. Historical geological work in the broader area has identified alkalic intrusive rocks, carbonatites, magnetite-rich zones, breccias, and alteration features that are often associated with REE-bearing systems.

According to Powermax, the Hopkins property exhibits geological characteristics considered favorable for carbonatite-related REE exploration. Historical work referenced by the company also identified nearby occurrences of monazite and cerium-lanthanum-calcium silicate mineral phases, although the company cautioned that nearby mineralization does not necessarily indicate similar mineralization on the Hopkins property itself.

The acquisition expands Powermax’s existing portfolio, which already includes the Cameron REE property in British Columbia, the Atikokan and Pinard projects in Ontario, and the Ogden Bear Lodge project in Wyoming.

Chief Executive Officer Paul Gorman said the Hopkins acquisition provides the company with a sizeable land package in a geological setting known for alkalic intrusive and carbonatite-related rocks commonly associated with rare earth exploration systems. “We believe the Property has strong early-stage exploration merit and fits well with our strategy of acquiring projects with favourable geology, infrastructure access and scalable exploration potential,” he said.

The company plans to begin a Phase 1 exploration program focused on refining exploration targets and identifying prospective zones across the property. Proposed work includes desktop geological and geophysical compilation, GIS modeling, field prospecting, mapping, rock and soil sampling, and airborne magnetic and gamma-ray spectrometric surveys. Radiometric surveying will also play a role in the early-stage program. Handheld scintillometers are expected to be used to identify radiometric anomalies that may correlate with REE-bearing mineralization. Subject to Phase 1 results, management indicated future work could include trenching, more detailed geophysics, and diamond drilling programs.

The expansion comes amid growing geopolitical focus on securing domestic supplies of rare earth elements and other critical minerals. REEs are essential components in permanent magnets, electric vehicles, wind turbines, military systems, advanced electronics, and numerous industrial technologies.

Global supply chains remain heavily concentrated in China, which currently dominates both REE mining and downstream processing capacity. According to industry estimates cited by the company, China controls roughly 60% of global rare earth mining and approximately 90% of processing activity. That concentration has intensified efforts by Western governments to support alternative supply chains. In both Canada and the United States, policymakers have increasingly classified rare earth elements as strategically important minerals tied to energy transition goals and national security priorities.

The United States has used measures including the Defense Production Act to direct funding toward domestic and allied critical mineral projects. Canadian companies may also qualify for certain North American funding initiatives tied to strategic mineral development.

Powermax remains at the exploration stage, and the Hopkins project itself is still in the early evaluation phase. The company emphasized that historical geological and mineralogical information has not yet been fully verified under current reporting standards and that further exploration will be required to determine the extent of any mineralized zones.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)and may include a paid advertisement.

• SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease.
• Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies.
• The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats.
• SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials.
• The company provides exposure to the expanding GLP-1 and obesity treatment markets, which are projected to grow significantly over the coming years.

SureNano (CSE: SURE) (OTCQB: SURNF) is a Canadian life sciences company positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. Blockbuster drugs such as Ozempic(R), Wegovy(R), and Mounjaro(R) have demonstrated both strong clinical outcomes and massive commercial success, driving intense competition among large pharmaceutical companies to develop next-generation treatments.

Within this landscape, SureNano represents a smaller, more agile entrant seeking to advance its own differentiated GLP-based therapeutic. Through its acquisition of GlucaPharm Inc., the company holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University, and is progressing the asset through the U.S. Food and Drug Administration (“FDA”) pathway with the goal of advancing it into clinical development.

The company’s strategy centers on combining therapeutic innovation with its foundational expertise in formulation and drug delivery to improve tolerability, administration, and patient experience. By focusing on a targeted development pathway within a rapidly expanding market dominated by large incumbents, SureNano aims to position its lead asset as a potential candidate for future partnership or acquisition as it progresses through clinical milestones.

The company is headquartered in Vancouver, British Columbia.

Portfolio

SureNano’s operations are now centered on the development of its lead therapeutic candidate, GEP-44, through its wholly owned subsidiary, GlucaPharm Inc. This asset represents the company’s primary focus as it advances its transition into a pharmaceutical development platform targeting metabolic disease.

GEP-44 is a novel, patented, monomeric peptide developed at Syracuse University that functions as a triple agonist targeting GLP-1 and peptide YY (“PYY”) receptors Y1 and Y2, which has demonstrated significant weight reduction and blood glucose normalization in preclinical studies, without the nausea and gastrointestinal side effects commonly associated with first-generation GLP-1 drugs currently on the market. This mechanism is designed to integrate glucose regulation, appetite suppression, and improved tolerability within a single molecule, addressing limitations commonly associated with first-generation GLP-1 therapies. GEP-44 is exclusively licensed from Syracuse University and represents a second-generation GLP opportunity targeting comparable or superior efficacy with improved patient tolerability.

In preclinical studies, GEP-44 demonstrated approximately 15% weight loss compared to 9% for liraglutide, along with a 39% reduction in food intake versus 20% for the comparator, while also improving glucose control and showing no observed gastrointestinal side effects such as nausea and vomiting.

The asset is being advanced through IND-enabling studies in collaboration with a contract research organization, with planned progression into clinical trials. SureNano’s foundational expertise in nanotechnology and formulation science, including its SureNano(TM) emulsifier platform, supports the development of potential non-injectable delivery formats such as oral, nasal, or sublingual administration.

The IND-enabling Good Laboratory Practice toxicology and pharmacology study program for GEP-44 is vital to de-risk the company’s lead candidate and is designed to support its strategy of launching a Phase I clinical trial in Australia, which is expected to be in collaboration with a premier global contract research organization (“CRO”), LabCorp, known for its expertise in preclinical development (subject to entering into definitive collaboration agreements). The pivotal, GLP-compliant package is specifically designed to assess safety, toxicology, and pharmacology across multiple species, including rodents and non-rodent primates, to evaluate the safety and feasibility of the approach for human clinical application. The studies will provide comprehensive data to determine the maximum tolerated dose (“MTD”), identify potential biomarkers for monitoring toxicity, assess the reversibility of toxic effects, and establish the safety margin needed for first-in-human studies.

Market Opportunity

SureNano is targeting the global market for metabolic disease therapeutics, which continues to expand due to rising rates of obesity and Type II diabetes. Company materials indicate that the GLP-1 therapeutic market was valued at approximately $24 billion in 2026 and is projected to reach approximately $33 billion by 2030.

The broader obesity treatment market, which includes all therapeutic approaches, was valued at approximately $15.9 billion in 2024 and is forecast to exceed $60 billion by 2030. These trends are supported by global prevalence estimates suggesting that approximately one billion people could be obese by 2030, reinforcing sustained demand for effective pharmacological interventions.

Within this landscape, GLP-based therapies are experiencing strong growth, with long-term projections indicating a multi-hundred-billion-dollar market opportunity over the coming decade. SureNano’s strategy is to position GEP-44 as a next-generation alternative within this category, with a focus on improved tolerability and delivery to expand patient adoption. SureNano’s platform is focused on advancing a differentiated GLP-1 asset with the potential for non-injectable administration, including oral, sublingual, or nasal delivery, which management believes could materially expand patient adoption and long-term market penetration.

As GEP-44 advances through IND, Phase I, and Phase II-III development towards FDA approval, management expects SureNano to be positioned as one of the only micro-cap public companies developing GLP-1 technology, with direct exposure to the multi-hundred-billion-dollar GLP-1 metabolic market, and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.

Leadership Team

Charles MaLette, Chief Executive Officer, President and Director, has more than 35 years of experience as an investment advisor with Canaccord Genuity Corp., where he focused on financing, analyzing, and advising public companies across multiple industries, and holds a degree in economics from the University of Calgary along with a teaching degree from the University of British Columbia.

James Bordian, Chief Financial Officer and Director, is a retired Chartered Accountant and Certified Internal Auditor with over 40 years of experience, including senior management roles at organizations such as Air Canada and BC Hydro, with expertise in financial reporting, tax planning, and business valuation.

Dr. Nihar Pandey, Chief Scientific Officer, is a biochemist and clinical researcher with more than 25 years of experience in drug discovery and development, having developed multiple IP-protected formulations, published extensively in peer-reviewed journals, and held roles at institutions including the University of Ottawa Heart Institute, Liponex Inc., and Health Canada.

Dr. Robert Doyle, Inventor and Advisor, is a medicinal chemist focused on drug development for obesity and type 2 diabetes, with specialization in peptide and protein design, recombinant expression, bioconjugate chemistry, and drug delivery. He joined Syracuse University in 2005, was named the Laura J. and L. Douglas Meredith Professor in 2016 and Dean’s Professor of Chemistry in 2022, and also holds an appointment as Associate Professor of Medicine at SUNY.

Dr. Peter Billing, Obesity Expert and Advisor, is a Mayo-trained metabolic bariatric surgeon, entrepreneur, and clinical investigator who serves as a courtesy medical staff member at Swedish First Hill and holds leadership roles including Medical Director at Transform SurgiCenter. He has a robust publication record on surgical treatments and bariatric procedures and was named a Top Doctor by Castle Connolly in 2023.

For more information, visit the company’s website at www.SureNano.com.

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF

Forward-Looking Information

Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, study and trial results, continued availability of capital and financing, and general economic, market, or business conditions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: expectations regarding the size of the markets the company operates in; the ability of the Company to successfully achieve its business objectives; plans for growth, political, social and environmental uncertainties; presence of laws and regulations which may impose restrictions in the markets where the Company operates; market volatility; fluctuations in investor sentiment; changes in the Company’s business plans; and trial and study results. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes.  The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. The Company does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.

Prospective Investors Should Consult with their Advisors.

The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation. All amounts are expressed in Canadian dollars unless otherwise noted. The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release or promotional content.

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.

• SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants.
• The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy.
• The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
• The company is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments.
• SureNano’s transition toward a pharmaceutical-focused model follows its acquisition of GlucaPharm, now operating in the rapidly expanding GLP market expected to hit $200 billion in sales by 2030.

SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has begun a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The company is initiating a Good Laboratory Practice (“GLP”) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (“FDA”) requirements, intended to support an Investigational New Drug (“IND”) application and represents a necessary step before first-in-human clinical trials. Against a backdrop of a rapidly expanding GLP market, SureNano is positioning itself as an agile entrant in the next-generation GLP-1 landscape having developed a patented high-performing second-generation incretin-based therapy after securing licensing rights to the GEP-44 compound developed by Syracuse University.

The GLP economic opportunity is substantial with the global GLP-1 receptor agonist market projections range from $100 billion to J.P. Morgan estimates of the broader incretin market to reach $200 billion by 2030, with ~25 million by 2030 patients using GLP-1 therapies in the United States alone. SureNano is participating in one of the fastest-growing and most commercially significant therapeutic markets in modern healthcare, with the GEP-44 contender that performs with higher tolerability and a friendly administration method, including greater weight loss, enhanced glucose control and an absence of the gastrointestinal side effects than first-generation therapies.

The studies are expected to be conducted in collaboration with Labcorp, a contract research organization (“CRO”) specializing in preclinical development services to support clinical development, subject to final agreements and funding (https://ibn.fm/xo3MQ).

According to the company, the GLP-compliant program will evaluate safety, toxicology, and pharmacology across multiple species, including rodents, non-rodents, and primates. The objective is to determine the maximum tolerated dose, identify biomarkers for monitoring toxicity, assess whether adverse effects are reversible, and establish safety margins for initial human testing. 

Following completion of the studies, SureNano plans to submit a Clinical Trial Notification in Australia, where it intends to begin Phase I trials. The company cited Australia’s regulatory framework and clinical research infrastructure as factors supporting an accelerated pathway to first-in-human studies.

Dr. Nihar Pandey, Chief Scientific Officer at SureNano, said the program marks a transition toward clinical-stage evaluation. “Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic,” said Dr. Pandey. “Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia.”

GEP-44, the company’s lead asset, is being developed through subsidiary GlucaPharm, which SureNano acquired earlier in 2026. The peptide was originally developed at Syracuse University and is designed as a multi-receptor agonist targeting pathways involved in glucose regulation and appetite control, designed as a triple agonist targeting GLP-1 and peptide YY (“PYY”) receptors (“Y1” and “Y2”), combining glucose regulation, appetite suppression, and improved tolerability within a single molecule.

It is positioned within the same therapeutic category as widely prescribed GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro. Those drugs have reshaped treatment approaches for obesity and type 2 diabetes and contributed to rapid growth in the GLP-1 market, which industry estimates place at tens of billions of dollars annually, with continued expansion expected.

SureNano said its candidate is designed to address some of the limitations associated with current therapies, including gastrointestinal side effects and the need for injectable delivery. The company is also exploring alternative delivery methods, including oral, sublingual, and nasal formats, which could affect patient adherence if successfully developed.

At this stage, GEP-44 remains in preclinical development, and its efficacy and safety in humans have not yet been established. The IND-enabling program is intended to generate the data required for regulators to evaluate whether human trials can proceed.

In parallel with its metabolic disease program, SureNano said it has begun discussions to acquire or license intellectual property related to Ibogaine formulations. Ibogaine is a naturally occurring psychoactive compound that has been studied for potential use in treating addiction and certain mental health conditions.

The company said it is in early-stage discussions with academic institutions and research groups regarding synthesis, formulation, and delivery technologies for Ibogaine and related compounds. No agreements have been finalized, and management noted that there is no assurance that any transaction will be completed.

Interest in Ibogaine has increased in recent years alongside broader research into psychedelic-assisted therapies. Recent regulatory developments in the United States, including IND clearance for Ibogaine-related studies, have opened the possibility of controlled clinical trials, although the field remains at an early stage.

SureNano’s approach reflects a broader shift in its business model. The company began with a focus on nanotechnology and formulation science, including the development of its SureNano(TM) emulsifier, a plant-derived compound used to improve stability and bioavailability in various applications.

Following the acquisition of GlucaPharm, the company has moved toward a pharmaceutical development strategy centered on therapeutic candidates with potential applications in large and growing healthcare markets. Obesity and type 2 diabetes remain among the most significant global health challenges, with prevalence rates rising and healthcare systems facing increasing costs associated with long-term management.

For more information, visit the company’s website at www.SureNano.com.

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF

Forward-Looking Information

Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, study and trial results, continued availability of capital and financing, and general economic, market, or business conditions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: expectations regarding the size of the markets the company operates in; the ability of the Company to successfully achieve its business objectives; plans for growth, political, social and environmental uncertainties; presence of laws and regulations which may impose restrictions in the markets where the Company operates; market volatility; fluctuations in investor sentiment; changes in the Company’s business plans; and trial and study results. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes.  The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. The Company does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.

Prospective Investors Should Consult with their Advisors.

The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation. All amounts are expressed in Canadian dollars unless otherwise noted. The Canadian Securities Exchange (CSE) has not reviewed and does no

• The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation
• The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents
• Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration

In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control. With biotech capital markets remaining selective and the IPO window constrained, alternative models that preserve shareholder value while advancing pipelines are gaining traction.

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within that shift. In an April 24 corporate update, the company outlined a partnership-driven strategy designed to unlock the value of its intellectual property portfolio while maintaining a capital-efficient operating structure.

A Capital-Efficient Framework

The foundation of Oncotelic’s approach is its joint venture with GMP Biotechnology. Through this structure, the company retains a 45% interest in GMP Bio while enabling the advancement of a complementary pipeline of oncology and rare disease candidates. The financial impact was notable: an independent third-party valuation contributed a $249 million increase to Oncotelic’s balance sheet for the most recent fiscal year.

For a clinical-stage company, that outcome represents more than a one-time accounting event. It provides a validated framework for advancing assets without issuing additional equity or taking on traditional financing obligations. Management has indicated that this model is being actively pursued across additional partnerships, with discussions ongoing.

“Our joint venture strategy has demonstrated the ability to unlock value through strategic partnerships,” said CEO Dr. Vuong Trieu, reinforcing the company’s intent to scale this approach across its broader portfolio.

Depth of Intellectual Property

The ability to execute a partnership-driven model depends heavily on the underlying assets. Oncotelic’s portfolio is anchored by an extensive intellectual property base, including more than 500 patent applications and 75 issued patents developed under the leadership of Dr. Trieu.

Rather than relying on a single lead candidate, the company can structure multiple co-development agreements, licensing deals, or joint ventures across distinct therapeutic targets. Its focus areas, including oncology, TGF-beta therapeutics, and rare pediatric indications, align with sectors where larger pharmaceutical companies often seek external innovation.

In this context, each patent represents a potential entry point for partnership, enabling the company to pursue parallel development pathways without concentrating risk in a single program.

The AI Acceleration Layer

In addition to its therapeutic pipeline, Oncotelic is advancing its proprietary PDAOAI platform, which integrates artificial intelligence into research, biomarker discovery, and regulatory workflows. The company recently announced the integration of approximately 28 million scientific abstracts into the platform, representing a broad aggregation of available scientific knowledge.

This dataset is being embedded into a robotics platform developed in collaboration with TechForce Robotics, with initial commercial deployments expected in the near term. The combined system is designed to automate elements of pharmaceutical development and manufacturing, improving efficiency while reducing reliance on manual processes.

Strategically, the AI layer extends beyond operational efficiency. By accelerating target identification and development timelines, it enhances the attractiveness of Oncotelic’s assets to potential partners, strengthening the economics of future collaborations.

Scaling the Partnership Model

Management has indicated that additional partnerships are under active negotiation, suggesting that the GMP Bio structure may represent the first in a series of similar arrangements. The combination of a validated joint venture framework, a deep intellectual property portfolio, and an operational AI platform provides flexibility in structuring deals tailored to specific assets and indications.

For investors evaluating microcap biotechnology companies, this model represents a departure from the traditional binary outcome associated with single-asset development. Instead of relying on a single clinical readout, Oncotelic is pursuing a portfolio-based strategy where value can be realized through multiple partnership-driven events.

In a sector where capital constraints often dictate outcomes as much as science, the ability to advance multiple programs while limiting dilution may prove to be a meaningful differentiator. Oncotelic’s approach suggests that, in today’s biotech environment, how a company structures its partnerships can be as important as the assets it develops.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Rising power demands from satellites, AI workloads, and space-based infrastructure are creating a new bottleneck in orbit
• Planet Ventures recent investment in Mantis Space highlights Planet’s strategy of backing foundational technologies in high-growth sectors
• The company recently announced the appointment of Dr. Bora to its leadership team, bringing experience in science, technology, and innovation

Planet Ventures (CSE: PXI) (OTC: PNXPF) is strategically positioning itself at the forefront of a critical shift in the global space economy: the race to build scalable energy infrastructure in orbit. As satellite networks expand and new applications such as space-based data centers and AI processing emerge, power—not launch capacity—is increasingly becoming the defining constraint on future growth.

For decades, the industry has focused on getting assets into space. Today, attention is shifting toward how those assets are powered. Mega-constellations, persistent satellite operations, and next-generation applications all require reliable, continuous energy, something current systems are not yet designed to deliver at scale. At the same time, rising energy demand on Earth, driven in part by artificial intelligence, is placing increasing strain on terrestrial grids, accelerating innovation beyond the planet.

Planet Ventures’ recent USD$200,000 investment in Mantis Space reflects this shift (ibn.fm/PAYyS). Mantis Space is developing what it describes as the world’s first orbital energy grid designed to deliver power directly to satellites, space habitats, and future lunar systems. This concept introduces a new category within the space economy: energy distribution as a service in orbit.

Momentum behind this thesis continues to build. As satellite volumes grow and mission complexity increases, energy is emerging as a key bottleneck. The rise of space-based data centers, designed to support energy-intensive AI workloads, further amplifies the need for scalable, always-on power solutions. While orbital environments offer advantages such as near-constant solar exposure, the absence of distribution infrastructure limits the ability to fully harness that energy.

Mantis Space is strategically positioning itself to solve this challenge. Its orbital grid is created to enable persistent satellite operations, defense applications, on-orbit manufacturing and future lunar infrastructure, capabilities generally seen as vital to a space economy expected to exceed $1 trillion in the coming years.

Planet Ventures, an investment issuer focused on aerospace and space innovation, seeks to provide shareholders with exposure to high-growth opportunities that are often limited to private markets. By targeting early-stage companies building foundational infrastructure, the firm is aligning its portfolio with long-term structural trends shaping the next phase of economic expansion.

Further reinforcing this strategic direction, Planet Ventures recently announced the appointment of Dr. Bora to its leadership team, bringing deep expertise in science, technology, and innovation. This addition underscores the company’s commitment to strengthening its technical and strategic capabilities as it scales its investment platform within the rapidly evolving space sector.

These developments highlight Planet Ventures’ broader mission: to invest in transformative technologies that enable the next wave of global growth. As the space economy matures, energy infrastructure is emerging not only as a critical opportunity, but also as a defining constraint.

For more information, visit www.PlanetVenturesinc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000 to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. 

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities

• Global energy markets are looking beyond traditional oil basins as reserve depletion and supply pressures intensify.
• Greenland Energy Company is focused on Greenland’s Jameson Land Basin, a high-potential and largely underexplored hydrocarbon region.
• The company aims to unlock frontier-scale energy resources that support long-term supply security and strategic diversification.

Greenland Energy (NASDAQ: GLND) is positioning itself within a shifting global energy landscape, as policymakers and industry leaders increasingly look beyond traditional oil-producing regions in search of new, scalable hydrocarbon resources. Years of underinvestment in upstream development, combined with reserve depletion in mature basins and rising geopolitical instability, are driving renewed interest in frontier exploration.

Ongoing tensions across key producing regions, and persistent disruptions at strategic chokepoints such as the Strait of Hormuz, continue to underscore the fragility of global energy supply chains. Despite ongoing diversification efforts, long-term energy security remains a central concern for Western economies, prompting increased focus on underexplored regions capable of supporting future production (ibn.fm/XgJFZ).

Within this context, Greenland is emerging as one of the last largely untapped hydrocarbon basins globally. Its expansive Arctic geology presents significant resource potential at a time when conventional discoveries are becoming harder to achieve. Rather than relying on aging fields, operators are increasingly evaluating frontier basins that offer district-scale opportunity and long-term development upside.

Greenland Energy Company’s primary focus is the Jameson Land Basin in eastern Greenland – a vast, historically underexplored region spanning more than two million acres across three onshore licenses that cover the entire petroleum basin. Unlike more mature oil provinces, where much of the accessible value has already been realized, Jameson Land represents a longer-duration exploration opportunity with meaningful upside potential (ibn.fm/9Z2YW).

Importantly, the basin is not without precedent. Between the 1970s and 1990s, Atlantic Richfield (“ARCO”) invested more than $275 million (inflation-adjusted) into seismic acquisition, field mapping, and geological evaluation across the region, identifying multiple large hydrocarbon targets. However, these efforts stopped short of drilling, leaving the basin effectively untested (ibn.fm/FZrd3).

Building on this historical foundation, Greenland Energy has reprocessed approximately 1,800 kilometers of legacy seismic data using modern imaging technologies, identifying more than 50 oil and gas leads and prospects. The basin has been compared geologically to prolific producing regions such as the North Sea and Alaska’s Prudhoe Bay, reinforcing its potential significance within the global energy landscape.

The company has structured its position through agreements that could allow it to earn up to a 70% interest in the basin, contingent on the drilling of initial exploration wells. Operational planning is actively advancing, with major industry service providers already engaged, including Halliburton for logistics and drilling support, IPT Well Solutions for project management, and Stampede Drilling for rig operations. These steps signal a transition from historical analysis toward tangible field execution.

From a resource perspective, the broader Arctic is estimated to contain approximately 13% of the world’s undiscovered conventional oil and 30% of its undiscovered natural gas. Within that framework, independent engineering analysis has suggested the Jameson Land Basin could hold significant recoverable oil potential, highlighting the scale of the opportunity—while still subject to the inherent uncertainties of exploration. As global demand for reliable energy sources continues to grow, Greenland Energy Company’s positioning reflects a broader shift toward securing long-term resource optionality. Its presence in Greenland places it at the intersection of exploration and strategic supply development, offering exposure to a region that could play a more prominent role in the global energy mix over time.

Taken together, these developments underscore the company’s core objective: to unlock large-scale hydrocarbon potential in one of the world’s least developed energy regions. By concentrating on the Jameson Land Basin, Greenland Energy Company is aligning its strategy with the increasing importance of resource security, long-term supply visibility, and basin-scale opportunity in a rapidly evolving energy environment.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND